High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Sellas said earlier laboratory work showed activity against pancreatic cancer cells resistant to RAS-targeting drugs.
J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.
ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.
Its IBRX stake jumped 27.5% to 243,678 shares worth $2.13 million, bringing both positions’ combined value to $2.86 million.
Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.
An AstraZeneca sales executive called the Phase 3 Regal trial a “game changer” for AML patients in their first or second complete remission.
ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.
Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined.
Sellas shares reached a swing high of $15.88 in late June before tumbling 42% to a July low of $9.19.
A German report claimed Regal hit its 80th event, but Sellas has not confirmed it.
The stock has gained over 20% in the past five days, marking its best week since early July.
Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.
Maxim Group described Moderna’s positive late-stage melanoma results as a “win for cancer vaccines,” arguing the surge in Moderna shares should support SELLAS if its key trial succeeds.
Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.
Vanguard held SLS and IBRX positions worth a combined $259 million at quarter-end.
The biotech, focused on novel cancer therapies, reported a net loss of $9.6 million, or $0.05 per share, for the quarter ended June 30.
Wall Street expects no quarterly revenue and a GAAP loss of $0.04 per share, narrowing from $0.05 previously.
Vontobel cut its holding by 16% but retained SLS shares worth $2.17 million.
A new Schedule 13G filing showed Vanguard Capital Management owned 9.67 million SLS shares as of June 30, 2026.
New York State Common Retirement Fund boosted its holding by 70%, while Commonwealth and Axxcess each raised stakes by about 17%.
Sellas estimated cash and cash equivalents of $138.3 million as of June 30.
CEO Angelos Stergiou said recently on “FOX & Friends” that AI and precision medicine could speed drug development and improve patient selection.
During an interview on Fox & Friends on Friday, Stergiou said AI will play a major role in helping cure cancer by enabling more precise treatments.
A new MD Anderson study found that survival was significantly shorter among older and higher-risk AML patients.
Shkreli reiterated his long-standing bearish stance on SLS, although he previously acknowledged making “a bad call” on Capricor after its positive HOPE-3 trial results.
Sellas is preparing for database lock, potential BLA-related regulatory work, and development of SLS009, its second AML drug.
The company entered a quiet period for trial-specific updates ahead of topline data.
Sellas Life Sciences bounced back by 12.26 percent on Friday to close at $13.19 apiece, as investors positioned portfolios ahead of a potentially company-defining clinical data release, supported by takeover speculations and growing institutional interest. The company is expected to report data from the phase 3 study evaluating its Galinpepimut-S (GPS) treatment candidate in patients […]
CEO Angelos Stergiou said he will discuss “novel clinical developments” involving GPS and SLS009 on Fox & Friends.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.